This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-28. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Lyophilised storage | −20 °C, dry, protected from light | Vials are sealed and allowed to reach room temperature before opening |
| Reconstituted storage | 2 to 8 °C, protected from light | Short-term holding; avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Water for injection or bacteriostatic water | Added slowly along the vial wall to reduce foaming and shear |
| Purity measurement | RP-HPLC with area normalisation | Acetonitrile-water gradient monitored at roughly 214 nm |
| Identity confirmation | Electrospray ionisation mass spectrometry | Observed mass compared against the calculated peptide mass |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Phenibut is a derivative of the inhibitory neurotransmitter GABA. Hence, it is a GABA analogue. Phenibut is specifically the analogue of GABA with a phenyl ring substituted in at the β-position. As such, its chemical name is β-phenyl-γ-aminobutyric acid, which can be abbreviated as β-phenyl-GABA. The presence of the phenyl ring allows phenibut to cross the blood–brain barrier significantly, unlike GABA. Phenibut also contains the trace amine β-phenethylamine in its structure. Phenibut is closely related to a variety of other GABA analogues including baclofen (β-(4-chlorophenyl)-GABA), 4-fluorophenibut (β-(4-fluorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), pregabalin ((S)-β-isobutyl-GABA), gabapentin (1-(aminomethyl)cyclohexane acetic acid), and GABOB (β-hydroxy-GABA). It has almost the same chemical structure as baclofen, differing from it only in having a hydrogen atom instead of a chlorine atom at the para position of the phenyl ring. Phenibut is also close in structure to pregabalin, which has an isobutyl group at the β position instead of phenibut's phenyl ring. A glutamate-derivative analogue of phenibut is glufimet (dimethyl 3-phenylglutamate hydrochloride).
Velmanase alfa, sold under the brand name Lamzede, is a medication used for the treatment of alpha-mannosidosis. Velmanase alfa is a recombinant human lysosomal alpha-mannosidase. The most common adverse reactions include hypersensitivity reactions including anaphylaxis, a severe, potentially life-threatening allergic reaction. Velmanase alfa was approved for medical use in the European Union in March 2018, and in the United States in February 2023. Velmanase alfa is the first enzyme replacement therapy approved in the US for the treatment of the non-central nervous system manifestations of alpha-mannosidosis. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
===== Response to stimuli ===== Serotonin is important in environmental response pathways, along with other neurotransmitters. Specifically, it has been found to be involved in auditory processing in social settings, as primary sensory systems are connected to social interactions. Serotonin is found in the IC structure of the midbrain, which processes specie specific and non-specific social interactions and vocalizations. It also receives acoustic projections that convey signals to auditory processing regions. Research has proposed that serotonin shapes the auditory information being received by the IC and therefore is influential in the responses to auditory stimuli. This can influence how an organism responds to the sounds of predatory or other impactful species in their environment, as serotonin uptake can influence aggression or social interaction.
20th century In the 1920s, the Canadian Pacific and Canadian National Railways cooperated together to lay an elaborate system of 4,500 metre pneumatic tubing between four of their offices to Postal Station A at Union Station in Toronto, Canada. There was also a connection to the mail room at the Royal York Hotel. The newspapers the Star and Telegram joined into the system, laying pipes. In the 1960s, Lockheed and MIT with the United States Department of Commerce conducted feasibility studies on a vactrain system powered by ambient atmospheric pressure and "gravitational pendulum assist" to connect cities on the country's East Coast. They calculated that the run between Philadelphia and New York City would average 174 meters per second, that is 626 km/h (388 mph). When those plans were abandoned as too expensive, Lockheed engineer L.K. Edwards founded Tube Transit, Inc. to develop technology based on "gravity-vacuum transportation". In 1967 he proposed a Bay Area Gravity-Vacuum Transit for California that would run alongside the then-under construction BART system. It was never built.
=== Side effects === Nicomorphine's side effects are similar to those of other opioids and include itching, nausea and respiratory depression. It is considered by doctors to be one of the better analgesics for the comprehensive mitigation of suffering, as opposed to purely clouding the noxious pain stimulus, in the alleviation of chronic pain conditions.
Sources: en.wikipedia.org
==== Concerns ==== An analysis conducted in late 2020 of premarket vaccine purchase commitments indicated that wealthy countries may receive their vaccines in 2020–21 while developing countries may be excluded from vaccinations until 2023–24. Data from April 2021 comports with this expectation since 25% of the population in high income countries have been vaccinated compared to only 0.2% in low income countries. The head of the World Health Organization said on 4 August 2021 that rich countries had administered about 100 doses per 100 people while poor countries had administered only about 1.5 doses for every 100 people, and therefore, in his estimation, it was important to prioritize vaccination in poor countries before offering booster vaccines in rich countries. The WHO Director General Tedros Adhanom Ghedreyesus raised concerns about rich countries hoarding vaccines at the expense of citizens in poorer nations who wait for vaccines to either become available or are donated. The WHO Regional Office of Africa highlighted vaccine discard in African countries, after Nigeria destroyed about 1 million donated doses of AstraZeneca vaccine after being donated with only a few weeks till expiration. Other countries such as Malawi, and South Sudan have either destroyed expired or close to expiring vaccines or paused donated shipments due to expiration concerns.
People today continue to honor Incan traditions and expand their knowledge in the building of rope bridges. "Each June in Huinchiri, Peru, four Quechua communities on two sides of a gorge join together to build a bridge out of grass, creating a form of ancient infrastructure that dates back at least five centuries to the Inca Empire." The previous Q’eswachaka Bridge is cut down and swept away by the Apurímac River current and a new bridge is built in its place. This tradition links the Quechua communities of the Huinchiri, Chaupibanda, Choccayhua, and Ccollana Quehue to their past ancestors.
An adjacent Cuban mechanised infantry battalion stationed sixteen kilometres to the south advanced to confront the paratroops during the attack, but suffered several delays due to strafing runs by South African Dassault Mirage III and Blackburn Buccaneer strike aircraft. In the first known engagement between South African and Cuban forces since the termination of Operation Savannah, five Cuban T-34-85 tanks and some infantry in BTR-152 armoured personnel carriers reached Cassinga while the paratroopers were being airlifted out by helicopter. This led to a protracted firefight in which Cuba acknowledged 16 dead and over 80 wounded. The Cassinga event was given special significance by Cuban historians such as Jorge Risquet, who noted that it marked the first time that "Cubans and Namibians shed their blood together fighting the South African [military]." While Cassinga was in the process of being destroyed, a South African armoured column attacked a network of guerrilla transit camps at Chetequera, code named "Objective Vietnam", which was only about thirty kilometres from the Cutline. Chetequera was much more heavily fortified than Cassinga and the SADF encountered fierce resistance. Unlike the latter, it had been scouted thoroughly by South African reconnaissance assets on the ground, and they were able to verify the absence of civilians with ample photographic and documentary evidence. The SADF suffered another 3 dead at Chetequera, in addition to 30 wounded. PLAN lost 248 dead and 200 taken prisoner.
careful modeling to anticipate the effect that an immunization campaign will have on the epidemiology of the disease in the medium to long term ongoing surveillance for the relevant disease following introduction of a new vaccine maintenance of high immunization rates, even when a disease has become rare
== Use == So far, biomass-based production of industrial microalgae has been widely applied in the fields from food and feed to high-value chemicals for pharmaceutical and ecological applications. Although the commercial cultivation of microalgae became increasingly popular, only algal biomass is processed to current products, while huge volumes of algae-free media are unexploited in flow through cultures and after biomass harvesting of batch cultures. Medium recycling to save culturing costs faces the big risk of growth inhibition. High volumes of spent media give rise to environmental pollution and cost of water and nutrition supply in cultivation when the media are discarded directly to the environment. Therefore the application of recycling methods motivated by the simultaneous generation of high value products from spent medium bears potential in commercial and environmental perspectives.
Sources: en.wikipedia.org
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.
Liquid chromatography coupled to mass spectrometry is the most common approach because it combines a retention time with a mass measurement. A chromatographic peak alone cannot establish which peptide is present, so mass determination or amino acid analysis is used as an orthogonal confirmation alongside the separation.
This depends on buffer, pH, and concentration, and published stability data for this peptide are limited. In practice laboratories work through a refrigerated solution within a few weeks and discard samples that show cloudiness or visible particles. Freezing and thawing repeatedly is generally discouraged.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.